Delta-Fly Pharma (4598) · FactAdvanced
Accelerating the development of novel therapeutics and nucleic acid medicines
First written in FY2019-Q2. 1 of 2 entries say "Advanced", first in FY2020-Q1. Latest entry: FY2020-Q1.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Approval Progress for Novel-Mechanism and Nucleic Acid DrugsA theme 2 companies write about · 0 as a headwind · 2 as a tailwind
0 other companies' latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2020-Q1AdvancedAnnual report
「2019年５月22日の中央社会保険医療協議会で国内初のCAR-T細胞療法剤「キムリア（一般名・チサゲンレクルユーセル）」の薬価が、１患者あたり3,349万3,407円と算定されるなど、併せて11成分17品目の新薬が承認されました」
新規作用・新技術に関する医薬品として、国内初のCAR-T細胞療法剤を含む新薬の承認実績が追加された。 - FY2019-Q2First statedAnnual report
「The U.S. Food and Drug Administration (FDA) approved patisiran, the world’s first siRNA drug, a nucleic-acid therapeutic. Inotersen, an antisense drug and nucleic-acid therapeutic already approved in Europe, was also nearing approval in the United States, accelerating the development of drugs with novel mechanisms of action.」
Describes overseas regulatory progress for nucleic-acid therapeutics and drugs with novel mechanisms as a change in the market environment.